

Maria Rosaria Ricciardi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6593316/publications.pdf>

Version: 2024-02-01

81
papers

3,136
citations

147801

31
h-index

161849

54
g-index

85
all docs

85
docs citations

85
times ranked

5153
citing authors

#	ARTICLE	IF	CITATIONS
1	ATM-ATRâ€“dependent up-regulation of DNAM-1 and NKG2D ligands on multiple myeloma cells by therapeutic agents results in enhanced NK-cell susceptibility and is associated with a senescent phenotype. <i>Blood</i> , 2009, 113, 3503-3511.	1.4	384
2	Targeting the leukemia cell metabolism by the CPT1a inhibition: functional preclinical effects in leukemias. <i>Blood</i> , 2015, 126, 1925-1929.	1.4	154
3	MEK inhibition enhances ABT-737-induced leukemia cell apoptosis via prevention of ERK-activated MCL-1 induction and modulation of MCL-1/BIM complex. <i>Leukemia</i> , 2012, 26, 778-787.	7.2	126
4	BCR ligation induced by IgM stimulation results in gene expression and functional changes only in IgVH unmutated chronic lymphocytic leukemia (CLL) cells. <i>Blood</i> , 2008, 112, 782-792.	1.4	121
5	Quantitative single cell determination of ERK phosphorylation and regulation in relapsed and refractory primary acute myeloid leukemia. <i>Leukemia</i> , 2005, 19, 1543-1549.	7.2	110
6	Cycling Status of CD34+ Cells Mobilized Into Peripheral Blood of Healthy Donors by Recombinant Human Granulocyte Colony-Stimulating Factor. <i>Blood</i> , 1997, 89, 1189-1196.	1.4	106
7	Genotoxic stress modulates the release of exosomes from multiple myeloma cells capable of activating NK cell cytokine production: Role of HSP70/TLR2/NF-kB axis. <i>OncImmunology</i> , 2017, 6, e1279372.	4.6	100
8	MDR1 protein expression is an independent predictor of complete remission in newly diagnosed adult acute lymphoblastic leukemia. <i>Blood</i> , 2002, 100, 974-981.	1.4	99
9	Growth-Inhibitory and Antiangiogenic Activity of the MEK Inhibitor PD0325901 in Malignant Melanoma with or without BRAF Mutations. <i>Neoplasia</i> , 2009, 11, 720-W6.	5.3	87
10	Multiple Myeloma Impairs Bone Marrow Localization of Effector Natural Killer Cells by Altering the Chemokine Microenvironment. <i>Cancer Research</i> , 2015, 75, 4766-4777.	0.9	86
11	Genotoxic Stress Induces Senescence-Associated ADAM10-Dependent Release of NKG2D MIC Ligands in Multiple Myeloma Cells. <i>Journal of Immunology</i> , 2015, 195, 736-748.	0.8	85
12	Reactive Oxygen Speciesâ€“ and DNA Damage Responseâ€“Dependent NK Cell Activating Ligand Upregulation Occurs at Transcriptional Levels and Requires the Transcriptional Factor E2F1. <i>Journal of Immunology</i> , 2014, 193, 950-960.	0.8	81
13	The IMiDs targets IKZF-1/3 and IRF4 as novel negative regulators of NK cell-activating ligands expression in multiple myeloma. <i>Oncotarget</i> , 2015, 6, 23609-23630.	1.8	78
14	Overcoming resistance to molecularly targeted anticancer therapies: Rational drug combinations based on EGFR and MAPK inhibition for solid tumours and haematologic malignancies. <i>Drug Resistance Updates</i> , 2007, 10, 81-100.	14.4	74
15	Inhibition of bromodomain and extra-terminal (BET) proteins increases NKG2D ligand MICA expression and sensitivity to NK cell-mediated cytotoxicity in multiple myeloma cells: role of cMYC-IRF4-miR-125b interplay. <i>Journal of Hematology and Oncology</i> , 2016, 9, 134.	17.0	72
16	PKC Î± mediates chemoresistance in acute lymphoblastic leukemia through effects on Bcl2 phosphorylation. <i>Leukemia</i> , 2004, 18, 505-512.	7.2	69
17	Cheâ€“induced inhibition of <sc>mTOR</sc> pathway enables stressâ€“induced autophagy. <i>EMBO Journal</i> , 2015, 34, 1214-1230.	7.8	66
18	Bortezomib and zoledronic acid on angiogenic and vasculogenic activities of bone marrow macrophages in patients with multiple myeloma. <i>European Journal of Cancer</i> , 2010, 46, 420-429.	2.8	65

#	ARTICLE	IF	CITATIONS
19	Inhibition of Glycogen Synthase Kinase-3 Increases NKG2D Ligand MICA Expression and Sensitivity to NK Cell-Mediated Cytotoxicity in Multiple Myeloma Cells: Role of STAT3. <i>Journal of Immunology</i> , 2013, 190, 6662-6672.	0.8	64
20	Drug-Induced Senescent Multiple Myeloma Cells Elicit NK Cell Proliferation by Direct or Exosome-Mediated IL15 Trans-Presentation. <i>Cancer Immunology Research</i> , 2018, 6, 860-869.	3.4	59
21	The mitogen-activated protein kinase (MAPK) cascade controls phosphatase and tensin homolog (PTEN) expression through multiple mechanisms. <i>Journal of Molecular Medicine</i> , 2012, 90, 667-679.	3.9	54
22	Purinergic signaling inhibits human acute myeloblastic leukemia cell proliferation, migration, and engraftment in immunodeficient mice. <i>Blood</i> , 2012, 119, 217-226.	1.4	52
23	Beyond Single Pathway Inhibition: MEK Inhibitors as a Platform for the Development of Pharmacological Combinations with Synergistic Anti-Leukemic Effects. <i>Current Pharmaceutical Design</i> , 2005, 11, 2779-2795.	1.9	48
24	ERK1/2 phosphorylation is an independent predictor of complete remission in newly diagnosed adult acute lymphoblastic leukemia. <i>Blood</i> , 2007, 109, 5473-5476.	1.4	46
25	MEK blockade converts AML differentiating response to retinoids into extensive apoptosis. <i>Blood</i> , 2007, 109, 2121-2129.	1.4	38
26	Energetic mitochondrial failing in vitiligo and possible rescue by cardiolipin. <i>Scientific Reports</i> , 2017, 7, 13663.	3.3	38
27	Co-targeting of Bcl-2 and mTOR pathway triggers synergistic apoptosis in BH3 mimetics resistant acute lymphoblastic leukemia. <i>Oncotarget</i> , 2015, 6, 32089-32103.	1.8	36
28	Therapeutic potential of MEK inhibition in acute myelogenous leukemia: rationale for œvertical and œlateral combination strategies. <i>Journal of Molecular Medicine</i> , 2012, 90, 1133-1144.	3.9	35
29	Targeting the Akt, GSK-3, Bcl-2 axis in acute myeloid leukemia. <i>Advances in Biological Regulation</i> , 2017, 65, 36-58.	2.3	33
30	MICA-129 Dimorphism and Soluble MICA Are Associated With the Progression of Multiple Myeloma. <i>Frontiers in Immunology</i> , 2018, 9, 926.	4.8	33
31	Aflatoxin Control in Maize by <i>Trametes versicolor</i> . <i>Toxins</i> , 2014, 6, 3426-3437.	3.4	32
32	PARP inhibitor ABT-888 affects response of MDA-MB-231 cells to doxorubicin treatment, targeting Snail expression. <i>Oncotarget</i> , 2015, 6, 15008-15021.	1.8	32
33	Interleukin-9 stimulates the proliferation of human myeloid leukemic cells. <i>Blood</i> , 1996, 87, 3852-3859.	1.4	31
34	The Activity of Differentiation Factors Induces Apoptosis in Polyomavirus Large T-Expressing Myoblasts. <i>Molecular Biology of the Cell</i> , 1998, 9, 1449-1463.	2.1	29
35	p38 MAPK differentially controls NK activating ligands at transcriptional and post-transcriptional level on multiple myeloma cells. <i>Oncimmunology</i> , 2017, 6, e1264564.	4.6	29
36	Innate immune activating ligand SUMOylation affects tumor cell recognition by NK cells. <i>Scientific Reports</i> , 2017, 7, 10445.	3.3	29

#	ARTICLE	IF	CITATIONS
37	Key Role of the CD56 ^{low} CD16 ^{low} Natural Killer Cell Subset in the Recognition and Killing of Multiple Myeloma Cells. <i>Cancers</i> , 2018, 10, 473.	3.7	29
38	The pan-class I phosphatidylinositol-3 kinase inhibitor NVP-BKM120 demonstrates anti-leukemic activity in acute myeloid leukemia. <i>Scientific Reports</i> , 2015, 5, 18137.	3.3	28
39	Reduced susceptibility to apoptosis correlates with kinetic quiescence in disease progression of chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2001, 113, 391-399.	2.5	26
40	Increased chronic lymphocytic leukemia proliferation upon IgM stimulation is sustained by the upregulation of miR-132 and miR-12. <i>Genes Chromosomes and Cancer</i> , 2015, 54, 222-234.	2.8	26
41	The tissue inhibitor of metalloproteinases 1 increases the clonogenic efficiency of human hematopoietic progenitor cells through CD63/PI3K/Akt signaling. <i>Experimental Hematology</i> , 2015, 43, 974-985.e1.	0.4	24
42	Biological Aspects of mTOR in Leukemia. <i>International Journal of Molecular Sciences</i> , 2018, 19, 2396.	4.1	24
43	Flt3L induces the ex-vivo amplification of umbilical cord blood committed progenitors and early stem cells in short-term cultures. <i>British Journal of Haematology</i> , 1999, 106, 133-141.	2.5	21
44	Bone Marrow Stromal Cell-Derived IL-8 Upregulates PVR Expression on Multiple Myeloma Cells via NF- κ B Transcription Factor. <i>Cancers</i> , 2020, 12, 440.	3.7	21
45	Tramesan, a novel polysaccharide from <i>Trametes versicolor</i> . Structural characterization and biological effects. <i>PLoS ONE</i> , 2017, 12, e0171412.	2.5	20
46	Cell cycle regulation and induction of apoptosis by IL-6 variants on the multiple myeloma cell line XG-1. <i>Annals of Hematology</i> , 1999, 78, 13-18.	1.8	19
47	Metabolic Reprogramming Promotes Myogenesis During Aging. <i>Frontiers in Physiology</i> , 2019, 10, 897.	2.8	19
48	Activation of liver X receptor upregulates the expression of the NKG2D ligands MICA and MICB in multiple myeloma through different molecular mechanisms. <i>FASEB Journal</i> , 2019, 33, 9489-9504.	0.5	19
49	Thrombopoietin and interleukin 11 have different modulatory effects on cell cycle and programmed cell death in primary acute myeloid leukemia cells. <i>Experimental Hematology</i> , 1999, 27, 1255-1263.	0.4	16
50	SIRT5 Inhibition Induces Brown Fat-Like Phenotype in 3T3-L1 Preadipocytes. <i>Cells</i> , 2021, 10, 1126.	4.1	16
51	A subset of chronic lymphocytic leukemia patients display reduced levels of PARP1 expression coupled with a defective irradiation-induced apoptosis. <i>Experimental Hematology</i> , 2012, 40, 197-206.e1.	0.4	15
52	A rare BCR-ABL1 transcript in Philadelphia-positive acute myeloid leukemia: case report and literature review. <i>BMC Cancer</i> , 2019, 19, 50.	2.6	15
53	Preclinical Antileukemia Activity of Tramesan: A Newly Identified Bioactive Fungal Metabolite. <i>Oxidative Medicine and Cellular Longevity</i> , 2017, 2017, 1-8.	4.0	13
54	Effects of IL-6 Variants in Multiple Myeloma: Growth Inhibition and Induction of Apoptosis in Primary Cells. <i>Leukemia and Lymphoma</i> , 2002, 43, 2369-2375.	1.3	12

#	ARTICLE	IF	CITATIONS
55	Functional and kinetic characterization of granulocyte colony-stimulating factor-primed CD34 ⁺ human stem cells. <i>British Journal of Haematology</i> , 2003, 123, 720-729.	2.5	12
56	Characterization of ABL1 expression in adult T-cell acute lymphoblastic leukemia by oligonucleotide array analysis. <i>Haematologica</i> , 2007, 92, 619-626.	3.5	12
57	The homeobox transcription factor MEIS2 is a regulator of cancer cell survival and IMiDs activity in Multiple Myeloma: modulation by Bromodomain and Extra-Terminal (BET) protein inhibitors. <i>Cell Death and Disease</i> , 2019, 10, 324.	6.3	11
58	Che-1/AATF-induced transcriptionally active chromatin promotes cell proliferation in multiple myeloma. <i>Blood Advances</i> , 2020, 4, 5616-5630.	5.2	10
59	mTOR Regulation of Metabolism in Hematologic Malignancies. <i>Cells</i> , 2020, 9, 404.	4.1	10
60	IgD cross-linking induces gene expression profiling changes and enhances apoptosis in chronic lymphocytic leukemia cells. <i>Leukemia Research</i> , 2013, 37, 455-462.	0.8	7
61	High expression levels of IP10/CXCL10 are associated with modulation of the natural killer cell compartment in multiple myeloma. <i>Leukemia and Lymphoma</i> , 2017, 58, 2493-2496.	1.3	6
62	Synergistic Induction of Apoptosis in Multiple Myeloma Cells by Simultaneous Inhibition of the Raf/MEK/ERK and BCL-2 Pathways. <i>Blood</i> , 2008, 112, 5161-5161.	1.4	4
63	Central nervous system immune reconstitution inflammatory syndrome after autologous stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2020, 55, 268-271.	2.4	3
64	Differential proteomic profile of leukemic CD34 ⁺ progenitor cells from chronic myeloid leukemia patients. <i>Oncotarget</i> , 2018, 9, 21758-21769.	1.8	3
65	Thrombopoietin, Interleukin-11, and Early-Acting Megakaryocyte Growth Factors in Human Myeloid Leukemia Cells. <i>Leukemia and Lymphoma</i> , 2000, 40, 179-190.	1.3	2
66	Apoptosis Susceptibility and Cell-Cycle Distribution in Cells from Myelodysplastic Syndrome Patients: Modulatory In-Vitro Effects of G-CSF and Interferon- γ . <i>Leukemia and Lymphoma</i> , 2004, 45, 1437-1443.	1.3	2
67	Protein Expression of p15 and p21 Plays an Unfavorable Prognostic Role in Adult Acute Lymphoblastic Leukemia (ALL) Patients Independently of Their Gene Promoter Methylation Status.. <i>Blood</i> , 2007, 110, 2802-2802.	1.4	2
68	The BCL-2 Antagonist ABT-737 Is Highly Effective on Primary Acute Lymphoblastic Leukemia Cells.. <i>Blood</i> , 2007, 110, 155-155.	1.4	1
69	Development of Mek inhibition (MEK-I)-Based Therapeutic Strategies in Acute Myeloid Leukemia (AML). <i>Blood</i> , 2008, 112, 860-860.	1.4	1
70	Bcl-2 and mTOR as Effective Targets for Molecular Therapy of Acute Lymphoblastic Leukemia. <i>Blood</i> , 2010, 116, 3228-3228.	1.4	1
71	Targeting Metabolic Pathways for Leukemia Treatment. <i>Blood</i> , 2012, 120, 1371-1371.	1.4	1
72	Abstract 350: Che-1/aatf-induced transcriptionally active chromatin promotes cell growth in multiple myeloma. , 2018, , .		1

#	ARTICLE	IF	CITATIONS
73	Molecular and Functional Effects of the Novel MEK Inhibitor PD0325901 in Preclinical Models of Human Leukemias.. Blood, 2006, 108, 254-254.	1.4	0
74	Functional Effects of the Bcl-2/Bcl-xL Inhibitor ABT-737 on Primary Cells from Smoldering Multiple Myeloma.. Blood, 2007, 110, 4782-4782.	1.4	0
75	Parallel Signaling through PI3K/AKT/mTOR Mediates Resistance to MEK Inhibition in Preclinical Models of Acute Myeloid Leukemia (AML): Synergistic Effects of Combined MEK and mTOR Inhibition.. Blood, 2009, 114, 594-594.	1.4	0
76	Preclinical Study to Sensitize Acute Lymphoblastic Leukemia Primary Cells by Combined mTOR and BCL-2 Inhibition with CCI-779 and ABT-737.. Blood, 2009, 114, 985-985.	1.4	0
77	Pre Clinical mTOR-Inhibition of Acute Lymphoblastic Leukemia Cells Synergizes with Pro-Apoptotic Target Therapy Through Mcl-1 Down-Regulation,. Blood, 2011, 118, 3581-3581.	1.4	0
78	Proteomic Signature of CD34+ Cells From Chronic Myeloid Leukemia Patients. Blood, 2012, 120, 3733-3733.	1.4	0
79	Modulation Of The Glycolytic Metabolism In Acute Myeloid Leukemia Cells. Blood, 2013, 122, 5045-5045.	1.4	0
80	Proteomic Profile Of CD34+ Cells From Chronic Myeloid Leukemia Patients and From Normal Donors. Blood, 2013, 122, 2712-2712.	1.4	0
81	Targeting Glycolysis and MAPK Pathway: A Combined Pre-Clinical Approach on Acute Myeloid Leukemia. Blood, 2016, 128, 2751-2751.	1.4	0